XORTX Therapeutics Inc. Common Stock
Market Cap
3.5M
Short interest (Jul 15)
1.4%
Net Short (Jul 27 ): -0.1%
Borrow Fee
118.45%
↓ 4.4%
Available Shares
70K
↓ 12.7%
Price Chart
Company Overview
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
Company Info
Market Data
Short Interest
Recent Changes
Quick Actions
Investment Risk
This is not financial advice. All investments carry risk. Do your own research before making investment decisions.